SRP3065
IGF-Binding Protein 6 human
recombinant, expressed in (BTI-Tn-5B1-4) High-5 Insect Cells, ≥95% (SDS-PAGE), ≥95% (HPLC), suitable for cell culture
Synonym(s):
IBP-6
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
51111800
NACRES:
NA.32
Recommended Products
biological source
human
recombinant
expressed in (BTI-Tn-5B1-4) High-5 Insect Cells
assay
≥95% (HPLC)
≥95% (SDS-PAGE)
form
lyophilized
potency
0.1-0.4 μg/mL
mol wt
23.0-30.0
packaging
pkg of 20 μg
technique(s)
cell culture | mammalian: suitable
impurities
<0.1 EU/μg endotoxin, tested
color
white to off-white
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... IGFBP6(3489)
General description
The IGFBP6 (insulin-like growth factor-binding protein 6) gene is mapped to human chromosome 12q13. It belongs to the IGFBP family of proteins. The protein has a IGF (insulin-like growth factor)-binding site and a thyroglobulin type-1 domain. IGFBPs are mainly required to regulate IGFs activities. IGFBP6 strongly interacts with IGF-2, but also interacts with IGF-1. It is also a hypoxia-inducible gene.
Recombinant human IGF-BP6 has a calculated mass of 22.3kDa and consists of 213 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.
Recombinant human IGF-BP6 has a calculated mass of 22.3kDa and consists of 213 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain.
Biochem/physiol Actions
IGFBP6 (insulin-like growth factor-binding protein 6) can suppress growth of various IGF-2 (insulin-like growth factor 2)-dependent tumors. However, it also exhibits IGF-independent activities. IGFBP is suggested as a serum biomarker for proliferative vitreoretinopathy. HIV (human immunodeficiency virus) infection results in downregulation of IGFBP6 via differential methylation.
Sequence
RCPGCGQGVQ AGCPGGCVEE EDGGSPAEGC AEAEGCLRRE GQECGVYTPN CAPGLQCHPP KDDEAPLRAL LLGRGRCLPA RAPAVAEENP KESKPQAGTA RPQDVNRRDQ QRNPGTSTTP SQPNSAGVQD TEMGPCRRHL DSVLQQLQTE VYRGAQTLYV PNCDHRGFYR KRQCRSSQGQ RRGPCWCVDR MGKSLPGSPD GNGSSSCPTG SSG
Physical form
Lyophilized from 10 mM Sodium Citrate, pH 3.5.
Reconstitution
Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Kininogen 1 and insulin-like growth factor binding protein 6: candidate serum biomarkers of proliferative vitreoretinopathy.
Yu J, et al.
Clinical & Experimental Optometry : Journal of the Australian Optometrical Association, 97, 72-72 (2014)
Prohibitin-2 binding modulates insulin-like growth factor-binding protein-6 (IGFBP-6)-induced rhabdomyosarcoma cell migration.
Fu P, et al.
The Journal of Biological Chemistry, 288, 29890-29890 (2013)
Whole genome methylation array reveals the down-regulation of IGFBP6 and SATB2 by HIV-1.
Zhang Y, et al.
Scientific Reports, 5, 10806-10806 (2015)
IGF binding protein-6 expression in vascular endothelial cells is induced by hypoxia and plays a negative role in tumor angiogenesis.
Zhang C, et al.
International Journal of Cancer. Journal International Du Cancer, 130, 2003-2003 (2012)
Leon A Bach
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 15(3), 185-192 (2005-05-26)
Insulin-like growth factor binding protein (IGFBP)-6 is unique among IGFBPs for its IGF-II binding specificity. IGFBP-6 inhibits growth of a number of IGF-II-dependent cancers, including rhabdomyosarcoma, neuroblastoma and colon cancer. Although the major action of IGFBP-6 appears to be inhibition
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service